SV Life Sciences and Novo A/S are among the four new investors supporting a Series B financing round for Karus Therapeutics Ltd of the UK. The investors have thus far committed $7.6 million to support programmes in inflammation and cancer. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
